A Randomized, Double-Blind, Placebo-Controlled Study of Atomoxetine in Japanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Takahashi, Michihiro; Takita, Yasushi; Yamazaki, Kosuke; Hayashi, Takashi; Ichikawa, Hironobu; Kambayashi, Yasuko; Koeda, Tatsuya; Oki, Junichi; Saito, Kazuhiko; Takeshita, Kenzo; Allen, Albert J.

doi:10.1089/cap.2008.0154

Cited by 36Attention Deficit Hyperactivity DisorderPharmaceutical studies and practicesDevelopmental and Educational Neuropsychology

A Randomized, Double-Blind, Placebo-Controlled Study of Atomoxetine in Japanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Takahashi, Michihiro, Takita, Yasushi, Yamazaki, Kosuke, Hayashi, Takashi, Ichikawa, Hironobu, Kambayashi, Yasuko, Koeda, Tatsuya, Oki, Junichi +3 more·2009·Journal of Child and Adolescent Psychopharmacology

DOI 10.1089/cap.2008.0154

Open this paper in CoChat — free account

Abstract

OBJECTIVES: Until the recent approval of methylphenidate (MPH), Japan had no approved treatment for attention-deficit/hyperactivity disorder (ADHD). The need still exists for an effective, safe, nonstimulant treatment. This first placebo-controlled Japan study of an ADHD nonstimulant therapy assessed atomoxetine efficacy and safety to determine the optimal dose for controlling ADHD symptoms in children and adolescents. METHODS: A total of 245 Japanese children and adolescents, aged 6-17 years and diagnosed with ADHD, were randomly assigned to receive placebo or one of three atomoxetine doses (0.5, 1.2, and 1.8 mg/kg per day) over 8 weeks. Symptoms were assessed with the Japanese Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator scored and integrated with teacher reports (ADHD RS-IV-J:I/Sch). Adverse events, vital signs, laboratory tests, and electrocardiograms (ECGs) were obtained for safety analysis. RESULTS: In all, 234 patients completed the study. Atomoxetine at 1.8 mg/kg per day was significantly superior to placebo in reducing ADHD symptoms (p = 0.01; one-sided). Decreased appetite and vomiting were significantly greater in the atomoxetine treatment groups; however, no clinically significant differences were observed. Two patients discontinued due to affect lability and headache. A linear dose-response and vital signs similar to those from other atomoxetine studies were observed. CONCLUSION: Atomoxetine provides an effective and safe nonstimulant option for the treatment of Japanese pediatric patients with ADHD.

Integrity signals

Registry

Crossref · 10.1089/cap.2008.0154

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Atomoxetine efficacy has been confirmed in populations around the world, including for children with oppositional defiant disorder or those who have received previous stimulant therapy.
“studies in populations around the world have continued to confirm its efficacy [78-81], including for children with oppositional defiant disorder [82] or those who have received previous stimulant therapy [83].”
From Advances in understanding and treating ADHD (2011) · cites this paper as [80]

Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial Reliability and Validity Data
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148 · see citing works
Clinical Practice Guideline: Diagnosis and Evaluation of the Child With Attention-Deficit/Hyperactivity Disorder
Committee on Quality Improvement, S. O. A.-D. D. (2000) · Pediatrics · doi:10.1542/peds.105.5.1158 · Cited by 1,076 · see citing works
A Test for Differences between Treatment Means When Several Dose Levels are Compared with a Zero Dose Control
Williams, D. A. (1971) · Biometrics · doi:10.2307/2528930 · Cited by 780 · see citing works
The Comparison of Several Dose Levels with a Zero Dose Control
Williams, D. A. (1972) · Biometrics · doi:10.2307/2556164 · Cited by 761 · see citing works
Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666 · see citing works
Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · see citing works
Self-citation
Health-Related Quality of Life in Children and Adolescents Who Have a Diagnosis of Attention-Deficit/Hyperactivity Disorder
Klassen, A. F., Miller, A., & Fine, S. (2004) · Pediatrics · doi:10.1542/peds.2004-0844 · Cited by 565 · see citing works
Once-Daily Atomoxetine Treatment for Children With Attention-Deficit/Hyperactivity Disorder, Including an Assessment of Evening and Morning Behavior: A Double-Blind, Placebo-Controlled Trial
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464 · see citing works
Self-citation
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz-Aigrain, É., Wilkinson, G. R., & Branch, R. A. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.194 · Cited by 453 · see citing works
Results From 2 Proof-of-Concept, Placebo-Controlled Studies of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
Spencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333 · see citing works
Debrisoquine/Sparteine Hydroxylation Genotype and Phenotype: Analysis of Common Mutations and Alleles of CYP2D6 in a European Population
Broly, F., Gaedigk, A., Heim, M. H., Eichelbaum, M. F., Mörike, K., & Meyer, U. (1991) · DNA and Cell Biology · doi:10.1089/dna.1991.10.545 · Cited by 219 · see citing works
Disposition and Metabolic Fate of Atomoxetine Hydrochloride: The Role of CYP2D6 in Human Disposition and Metabolism
Sauer, J., Ponsler, G. D., Mattiuz, E. L., Long, A. J., Witcher, J. W., Thomasson, H. R., & DESANTE, K. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.1.98 · Cited by 152 · see citing works
A Randomized, Placebo-Controlled Study of Once-Daily Atomoxetine in the School Setting in Children With ADHD
Weiss, M., Tannock, R., Kratochvil, C., Dunn, D., Velez-Borras, J., Thomason, C., Tamura, R., Kelsey, D., Stevens, L., & Allen, A. J. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000163280.47221.c9 · Cited by 147 · see citing works
Self-citation
An Open-Label, Dose-Ranging Study of Atomoxetine in Children with Attention Deficit Hyperactivity Disorder
Spencer, T., Biederman, J., Heiligenstein, J. H., Wilens, T. E., Faries, D. E., Prince, J. B., Faraone, S. V., Rea, J., Witcher, J. W., & Zervas, S. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/10445460152595577 · Cited by 147 · see citing works
Identification of the Human Cytochromes P450 Responsible for Atomoxetine Metabolism
Ring, B. J., Gillespie, J. S., Eckstein, J. A., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.3.319 · Cited by 133 · see citing works
The Link Between Health-Related Quality of Life and Clinical Symptoms Among Children with Attention-Deficit Hyperactivity Disorder
MATZA, L. S., RENTZ, A. M., SECNIK, K., SWENSEN, A. R., REVICKI, D. A., MICHELSON, D., SPENCER, T., NEWCORN, J. H., & KRATOCHVIL, C. J. (2004) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200406000-00005 · Cited by 119 · see citing works
Abuse liability assessment of atomoxetine in a drug-abusing population
Jasinski, D. R., Faries, D. E., Moore, R. J., Schuh, L. M., & Allen, A. J. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.01.008 · Cited by 87 · see citing works
Self-citation
Efficacy of Atomoxetine Versus Placebo in School-Age Girls With Attention-Deficit/Hyperactivity Disorder
Biederman, J., Heiligenstein, J. H., Faries, D. E., Galil, N., Dittmann, R., Emslie, G. J., Kratochvil, C. J., Laws, H. F., Schuh, K. J., & Atomoxetine ADHD Study Group (2002) · PEDIATRICS · doi:10.1542/peds.110.6.e75 · Cited by 87 · see citing works
Atomoxetine <i>versus</i> Methylphenidate in Paediatric Outpatients with Attention Deficit Hyperactivity Disorder: A Randomized, Double-Blind Comparison Trial
Wang, Y., Zheng, Y., Du, Y., Song, D. H., Shin, Y.-J., Cho, S. C., Kim, B. N., Ahn, D. H., Marquez-Caraveo, M. E., Gao, H., et al. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670601057767 · Cited by 84 · see citing works
A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD
Buitelaar, J. K., Danckaerts, M., Gillberg, C., Zuddas, A., Becker, K., Bouvard, M. P., Fagan, J., Gádoros, J., Harpin, V., Hazell, P., et al. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-0401-3 · Cited by 76 · see citing works
Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
Horai, Y., Taga, J., Ishizaki, T., & Ishikawa, K. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03609.x · Cited by 29 · see citing works
No association between CYP2D6 polymorphisms and personality trait in Japanese
Iwashima, K., Yasui‐Furukori, N., Kaneda, A., Saito, M., Nakagami, T., Sato, Y., & Kaneko, S. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02858.x · Cited by 21 · see citing works

Flagged first, then by citations

Sorted by citations

Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression
Schwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.005 · Cited by 166 · see citing works
Advances in understanding and treating ADHD
Antshel, K. M., Hargrave, T. M., Simonescu, M., Kaul, P., Hendricks, K., & Faraone, S. V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-72 · Cited by 140 · see citing works
The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113 · see citing works
Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: A meta-analysis with focus on bupropion
Stuhec, M., Munda, B., Svab, V., & Locatelli, I. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.03.006 · Cited by 83 · see citing works
Atomoxetine and Methylphenidate Treatment in Children with ADHD: The Efficacy, Tolerability and Effects on Executive Functions
Yildiz, O., Şişmanlar, Ş. G., Memik, N. Ç., Karakaya, İ., & Ağaoğlu, B. (2010) · Child Psychiatry & Human Development · doi:10.1007/s10578-010-0212-3 · Cited by 74 · see citing works
Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: Focus on clinical efficacy and safety
Bushe, C., & Savill, N. C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113478475 · Cited by 72 · see citing works
The Efficacy of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Clinical Research
Savill, N. C., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., & Coghill, D. (2015) · CNS Drugs · doi:10.1007/s40263-014-0224-9 · Cited by 57 · see citing works
Meta-Analysis of Suicide-Related Behavior or Ideation in Child, Adolescent, and Adult Patients Treated with Atomoxetine
Bangs, M. E., Wietecha, L. A., Wang, S., Buchanan, A. S., & Kelsey, D. K. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0005 · Cited by 51 · see citing works
The Effects of Long-Acting Stimulant and Nonstimulant Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials
Cerrillo-Urbina, A. J., García-Hermoso, A., Pardo-Guijarro, M. J., Sánchez-López, M., Santos-Gómez, J. L., & Martínez-Vizcaíno, V. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0151 · Cited by 44 · see citing works
Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine
Roskell, N. S., Setyawan, J., Zimovetz, E. A., & Hodgkins, P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.904772 · Cited by 42 · see citing works
Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison
Joseph, A., Ayyagari, R., Xie, M., Cai, S., Xie, J., Huss, M., & Sikirica, V. (2017) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-017-0962-6 · Cited by 38 · see citing works
Cardiovascular Measures in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Who Are New Users of Methylphenidate and Atomoxetine
Arcieri, R., Germinario, E. A. P., Bonati, M. R., Masi, G., Zuddas, A., Vella, S., Chiarotti, F., & Panei, A. T. I. A. R. P. (2012) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0014 · Cited by 36 · see citing works
Pharmacokinetics, Safety, and Tolerability of Atomoxetine and Effect of CYP2D6*10/*10 Genotype in Healthy Japanese Men
Matsui, A., Azuma, J., Witcher, J. W., Long, A. J., Sauer, J., Smith, B. P., DESANTE, K. A., Read, H. A., Takahashi, M., & Nakano, M. H. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011398657 · Cited by 36 · see citing works
Self-citation
An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments
Li, Y., Gao, J., He, S., Zhang, Y., & Wang, Q. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0179-6 · Cited by 26 · see citing works
Attention-Deficit/Hyperactivity Disorder Drugs and Growth: An Italian Prospective Observational Study
Germinario, E. A. P., Arcieri, R., Bonati, M. R., Zuddas, A., Masi, G., Vella, S., Chiarotti, F., & Panei, A. T. I. A. R. P. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0086 · Cited by 21 · see citing works
An open‐label, dose‐titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention‐deficit/hyperactivity disorder
Takahashi, M., Takita, Y., Goto, T., Ichikawa, H., Saito, K., Matsumoto, H., & Tanaka, Y. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02159.x · Cited by 20 · see citing works
Self-citation
Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder
Takahashi, M., Goto, T., Takita, Y., Chung, S., Wang, Y., & Gau, S. S. (2012) · Asia-Pacific Psychiatry · doi:10.1111/j.1758-5872.2012.00204.x · Cited by 17 · see citing works
Self-citation
Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder
Luan, R., Mu, Z., Yue, F., & He, S. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00229 · Cited by 11 · see citing works
Atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology
Gayleard, J., & Mychailyszyn, M. P. (2017) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-017-0216-y · Cited by 12 · see citing works
Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder
Ichikawa, H., Miyajima, T., Yamashita, Y., Fujiwara, M., Fukushi, A., & Saito, K. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0076 · Cited by 10 · see citing works
Self-citation
Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder
Saito, T., Yamashita, Y., Tomoda, A., Okada, T., Umeuchi, H., Iwamori, S., Shinoda, S., Mizuno‐Yasuhira, A., Urano, H., Nishino, I., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02932-2 · Cited by 10 · see citing works
Self-citation
Efficacy and Safety of Atomoxetine in the Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder
Kohn, M. R., Tsang, T. W., & Clarke, S. D. (2012) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s7868 · Cited by 9 · see citing works
A Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine in Korean Pediatric Outpatients with Attention-Deficit/Hyperactivity Disorder
Cho, S.-C., Lee, S. I., Yoo, H. K., Song, D., Ahn, D.-H., Shin, D. W., Yum, S. Y., Walton, R., & Mendez, L. (2011) · Psychiatry Investigation · doi:10.4306/pi.2011.8.2.141 · Cited by 7 · see citing works
Efficacy and safety of SDT ‐001, a dual‐task digital device, in managing attention‐deficit/hyperactivity disorder symptoms in children and adolescents: a phase 3, randomized, standard treatment‐controlled study
Mikami, K., Miyajima, T., Nishino, R., Kawazoe, N., Kinoshita, Y., Okada, T., & Fukuju, H. (2025) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13833 · Cited by 6 · see citing works
Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder
Hu, X.-J., Pan, L., & Li, W. (2022) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/155802 · Cited by 6 · see citing works
The Dose-Response Relationship of Atomoxetine for the Treatment of Children With ADHD: A Systematic Review and Dose-Response Meta-Analysis of Double-Blind Randomized Placebo-Controlled Trials
Terao, I., Kodama, W., & Tsuda, H. (2023) · Journal of Attention Disorders · doi:10.1177/10870547231214988 · Cited by 6 · see citing works
A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): Rationale and design
Tsang, T. W., Kohn, M. R., Hermens, D. F., Clarke, S. D., Clark, C. R., Efron, D., Cranswick, N., Lamb, C., & Williams, L. M. (2011) · Trials · doi:10.1186/1745-6215-12-77 · Cited by 6 · see citing works
A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy
Sohn, M., Talbert, J., Moga, D. C., & Blumenschein, K. (2016) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-016-0198-1 · Cited by 6 · see citing works
Clinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: a systematic review and economic model
Tomlinson, E., Ward, M., Walker, J. G., Benavente, M., Wang, H., Cooper, C., Jones, H. E., Owen‐Smith, A., Manzano, C. L., James, S., et al. (2025) · Health Technology Assessment · doi:10.3310/drdr7171 · Cited by 3 · see citing works
Exploratory study of dual‐task digital device in children and adolescents with attention‐deficit/hyperactivity disorder
Mikami, K., Miyajima, T., Nishino, R., Kawazoe, N., Ochiai, T., Okada, T., & Fukuju, H. (2025) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70089 · Cited by 3 · see citing works
Atomoksetin Tedavisi Alan Çocuk ve Ergenlerde Karaciğer Enzimleri ve Bilirubin Düzeyleri / Liver Enzymes and Bilirubin Levels during Atomoxetine Treatment in Children and Adolescents
Üneri, Ö. Ş., Çöpür, M., Tanıdır, C., Güneş, H., & Erdoğan, A. (2012) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.5350/dajpn2013260102 · Cited by 1 · see citing works
A Review on Atomoxetine in the Treatment of Attention Deficit Hyperactivity Disorder
Rajan, K. R. V. (2014) · African Journal of Psychiatry · doi:10.4172/psychiatry.1000146 · Cited by 1 · see citing works
THE OFF-LABEL USE OF ATYPICAL ANTIPSYCHOTICS AND ITS IMPACT ON ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Sohn, M. (2014) · UKnowledge (University of Kentucky)
Insignificant Effects of Atomoxetine on Thyroid Functions in Children and Adolescents with Attention Deficit and Hyperactivity Disorder in Short Term
Tanıdır, C., Tanıdır, İ. C., Bahalı, K., Güneş, H., Adaletli, H., Öztürk, E., Ünüvar, T., & Üneri, Ö. Ş. (2016) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20150505104526
Current awareness in human psychopharmacology
(2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1061
Additional file 1 of Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder
Saito, T., Yamashita, Y., Tomoda, A., Okada, T., Umeuchi, H., Iwamori, S., Shinoda, S., Mizuno‐Yasuhira, A., Urano, H., Nishino, I., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212625
Self-citation

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on Once-Daily Atomoxetine Hydrochloride in Taiwanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Gau, S. S., Huang, Y., Soong, W., Chou, M., Chou, W., Shang, C., Tseng, W., Allen, A. J., & Lee, P. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.0091 · Cited by 65 · see citing works
Self-citation
Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666 · see citing works
An Open-Label, Dose-Ranging Study of Atomoxetine in Children with Attention Deficit Hyperactivity Disorder
Spencer, T., Biederman, J., Heiligenstein, J. H., Wilens, T. E., Faries, D. E., Prince, J. B., Faraone, S. V., Rea, J., Witcher, J. W., & Zervas, S. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/10445460152595577 · Cited by 147 · see citing works
Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · see citing works
Self-citation
Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder
Montoya, A. G., Amaia Hervas, G., Cardo, E., Artigas-Pallarés, J., Mardomingo, M. J., Alda, J. A., Gastaminza, X., García-Polavieja, M. J., Gilaberte, I., & Escobar, R. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903316152 · Cited by 64 · see citing works

Authors: Takahashi, M., Takita, Y., Yamazaki, K., Hayashi, T., Ichikawa, H., Kambayashi, Y., Koeda, T., Oki, J., Saito, K., Takeshita, K., & Allen, A. J.
Affiliations: Eli Lilly (Japan) (JP)
Mejiro University (JP)
Yamaguchi Prefectural University (JP)
Tokyo Metropolitan Umegaoka Hospital, Tokyo, Japan.
Chuo University (JP)
Tottori University (JP)
Asahikawa Kosei Hospital (JP)
Kohnodai Hospital, National Center for Global Health and Medicine (JP)
Fukuoka Social Medical Welfare University (JP)
Eli Lilly (United States) (US)
Corresponding author: Takahashi, Michihiro
ORCID: Yamazaki, Kosuke
Saito, Kazuhiko
Venue: Journal of Child and Adolescent Psychopharmacology
Publisher: SAGE Publications
Published: 2009-08
Volume: 19
Issue: 4
Pages: 341-350
ISSN: 1044-5463 (ISSN-L)
1557-8992
DOI: 10.1089/cap.2008.0154
OpenAlex: W2021696244
Cited by: 36
References: 22
Citations by year: 2025: 3 · 2023: 1 · 2022: 1 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 2 · 2014: 4 · 2013: 3 · 2012: 4
FWCI: 2.27
Type: journal article
Language: en
Open access: closed
Licence: www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
Locations: Journal of Child and Adolescent Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Funders: Eli Lilly Japan
Janssen Pharmaceuticals
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
Keywords: atomoxetine, attention deficit hyperactivity disorder, dose-response relationship, ADHD symptom reduction, drug safety, appetite loss, vomiting, vital signs, ADHD-RS-IV
MeSH terms: Atomoxetine Hydrochloride, Adolescent, Age Factors, Attention Deficit Disorder with Hyperactivity, Child, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Propylamines, Asian People

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Randomized, Double-Blind, Placebo-Controlled Study of Atomoxetine in Japanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks